StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck invanz (ertapenem, legacy) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q4 2022
41
Period ended Dec 31, 2022
Change on a year earlier
-8.9%
45 in Q4 2021
History
28 quarters
Since Q1 2016
Sources
7
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInvanz (ertapenem, legacy) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2022Dec 31, 202241-8.9%Form 10-K (filed 2023-02-24) ↗
Q3 2022Sep 30, 202250-5.7%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202246-4.2%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2022Mar 31, 202252-8.8%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q4 2021Dec 31, 202145-15.1%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q3 2021Sep 30, 202153+3.9%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202148+11.6%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2021Mar 31, 202157-10.9%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q4 2020Dec 31, 202053-7.0%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2020Sep 30, 202051-10.5%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q2 2020Jun 30, 202043-44.9%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q1 2020Mar 31, 202064-11.1%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q4 2019Dec 31, 201957-3.4%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2019Sep 30, 201957-58.4%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q2 2019Jun 30, 201978-47.7%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q1 2019Mar 31, 201972-52.3%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Breakdown

What makes up invanz (ertapenem, legacy) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Invanz (ertapenem, legacy) — Worldwide sales ($M) ($M), quarterly Q1 2016–Q4 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_invanz

See every metric in the Merck KPI table. Data updated Oct 26, 2026.